使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings, and welcome to the Align Technology Second Quarter 2017 Earnings Call. (Operator Instructions) As a reminder, this conference is being recorded.
各位好,歡迎參加 Align Technology 2017 年第二季財報電話會議。(接線員指示) 提醒各位,本次會議將被錄音。
I would now like to turn the conference over to your host, Ms. Shirley Stacy, VP, Corporate and Investor Communications. Ms. Stacy, you may begin.
現在我想把會議交給本次會議主持人——企業與投資人溝通副總裁 Shirley Stacy 女士。Stacy 女士,您可以開始了。
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO; and John Morici, CFO.
各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同出席電話會議的有總裁兼執行長 Joe Hogan,以及財務長 John Morici。
We issued second quarter 2017 financial results today via Marketwired, which is available on our website at investor.aligntech.com.
我們今天透過 Marketwired 發布了 2017 年第二季財務結果,您可在我們網站 investor.aligntech.com 上查閱。
Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 p.m. Eastern Time through 5:30 p.m. Eastern Time on August 10. To access the telephone replay, domestic callers should dial (877) 660-6853 with conference number 13665263 followed by pound. International callers should dial (201) 612-7415 with the same conference number.
今天的電話會議將以音訊網路直播,並會在我們網站上保存約 12 個月。電話重播將於今日約下午 5:30(美東時間)提供,並持續至 8 月 10 日下午 5:30(美東時間)。如需收聽電話重播,美國境內來電者請撥 (877) 660-6853,輸入會議編號 13665263 後按井字鍵。國際來電者請撥 (201) 612-7415,並使用相同的會議編號。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the third quarter of 2017. These forward-looking statements are only predictions and involve risks and uncertainties that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission.
提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2017 年第三季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會提交的定期報告中更詳細說明。
Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements. We have posted historical financial statements, including the corresponding reconciliations and our second quarter conference call slides on our website under Quarterly Results. Please refer to these files for more detailed information.
實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。我們已在網站「季度結果」專區發布歷史財務報表(含相應調節表)以及第二季電話會議簡報投影片。如需更詳細資訊,請參閱這些檔案。
With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我把電話交給 Align Technology 總裁兼執行長 Joe Hogan。Joe?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Thanks, Shirley. Good afternoon, and thanks for joining us.
謝謝你,Shirley。各位下午好,感謝各位加入我們。
On our call today, I'll provide some highlights from the quarter and then briefly discuss the performance of our 2 operating segments, clear aligners and scanners. John will provide more detail on our financial results and discuss our outlook for the third quarter. Following that, I'll come back and summarize a few key points and open up the call to questions.
在今天的電話會議中,我將先分享本季的一些重點,接著簡要說明我們兩個營運部門——透明牙套與掃描器——的表現。John 將更詳細說明我們的財務結果,並討論第三季展望。之後我會回來總結幾個關鍵重點,並開放提問。
Our second quarter results were better than expected across all key financial metrics, including revenue, volume, margins and EPS. Q2 revenues increased 32.3% year-over-year, driven by strong Invisalign case shipments across all channels and especially in the teen segment. Solid execution of our strategy and key investments continued to deliver strong growth across the board with record Invisalign volume in almost every geography. Q2 also had an all-time high of nearly 5,000 newly trained doctors in the quarter for the first time ever. And our iTero scanner business also performed well this quarter with revenues up 36.7% year-over-year.
我們第二季的結果在所有關鍵財務指標上都優於預期,包括營收、出貨量、毛利率與每股盈餘(EPS)。第二季營收年增 32.3%,主要受惠於各通路 Invisalign 病例出貨強勁,尤其是青少年(teen)市場。我們策略的扎實執行與關鍵投資持續帶動全面性的強勁成長,幾乎每個地區的 Invisalign 出貨量都創下新高。第二季也首次在單季新增受訓醫師接近 5,000 位,創歷史新高。此外,我們的 iTero 掃描器業務本季表現亦佳,營收年增 36.7%。
For Q2, North American Invisalign case volume was up 10.3% sequentially and 27.6% year-over-year, reflecting strong year-over-year growth from both orthodontists and GP dentist channels. Continued uptake with teens drove Invisalign growth in North America and contributed to another record quarter for ortho volumes up 34.5% year-over-year and in utilization up to 13.6 cases per doctor.
第二季北美 Invisalign 病例量較前一季成長 10.3%,年增 27.6%,反映矯正專科醫師與一般牙醫(GP)通路皆有強勁的年增成長。青少年市場的持續採用帶動北美 Invisalign 成長,並促成矯正通路再創紀錄的一季:矯正病例量年增 34.5%,每位醫師的使用量提升至 13.6 例。
Q2 volume for North America GP dentist increased 18.9% year-over-year, primarily reflecting continued expansion of our GP customer base and utilization growth, which increased to a record 3.3 cases per doctor. Q2 was the first quarter we offered Invisalign Lite in North America, and we saw solid uptake especially among GP dentists. Invisalign Lite includes up to 14 stages of aligners and is intended to treat simple to moderate cases.
第二季北美一般牙醫(GP)通路的病例量年增 18.9%,主要反映我們 GP 客戶基礎持續擴張,以及使用量成長;每位醫師的使用量提升至創紀錄的 3.3 例。第二季是我們首次在北美推出 Invisalign Lite,我們看到不錯的採用情況,尤其是在一般牙醫之間。Invisalign Lite 最多包含 14 個階段的牙套,旨在治療簡單至中度的病例。
Q2 Invisalign volume for international doctors was up 13.6% sequentially and 37.4% year-over-year, driven primarily by new customers in both EMEA and APAC regions. In EMEA, Q2 volumes were up 33.2% year-over-year. All 5 of our core European markets showed record growth rates led by Spain and the U.K. Expansion markets also had record volume with over 50% year-over-year growth led by Central and Eastern Europe and the Benelux.
第二季國際市場醫師的 Invisalign 病例量較前一季成長 13.6%,年增 37.4%,主要由 EMEA 與 APAC 兩大區域的新客戶所帶動。在 EMEA,第二季病例量年增 33.2%。我們五個歐洲核心市場皆呈現創紀錄的成長率,其中以西班牙與英國領先。擴張市場的病例量也創新高,年增超過 50%,主要由中東歐與比荷盧(Benelux)帶動。
In Asia Pacific, Q2 volumes were up 44.4% year-over-year, led by China, where we trained over 1,000 doctors for the first time; followed by growth from Southeast Asia, Japan and ANZ.
在亞太地區,第二季病例量年增 44.4%,由中國領先;我們首次在中國單季培訓超過 1,000 位醫師;其次為東南亞、日本與澳洲及紐西蘭(ANZ)的成長。
Turning to the teen market. Over 55,000 teenagers started treatment with Invisalign clear aligners in Q2, up 12.6% sequentially and 37.6% year-over-year, reflecting continued acceleration above adult case volume growth.
接著談青少年市場。第二季有超過 55,000 名青少年開始使用 Invisalign 透明牙套治療,較前一季成長 12.6%,年增 37.6%,顯示其加速成長幅度持續高於成人病例量的成長。
North America ortho teen cases increased 11.6% sequentially and 42.1% year-over-year compared to adult cases of 9.8% and 30.5%, the third consecutive quarter teen growth rate that has been above adults. International case shipments to teen patients increased both 13.7% sequentially and 40.5% year-over-year as well.
北美矯正通路的青少年病例較前一季成長 11.6%,年增 42.1%;相較之下,成人病例分別為 9.8% 與 30.5%。這是青少年成長率連續第三季高於成人。國際市場對青少年患者的病例出貨亦分別較前一季成長 13.7%,年增 40.5%。
In Q2, we expanded commercialization of Invisalign treatment with mandibular advancement to select countries in EMEA and APAC. [MAS], as we call it, is the first clear aligner solution for Class II correction that advances the mandible while moving teeth at the same time.
第二季,我們將具下顎前移功能的 Invisalign 治療(mandibular advancement)商業化推廣擴展至 EMEA 與 APAC 的部分國家。[MAS](我們的稱呼)是第一個用於第二類咬合(Class II)矯正的透明牙套解決方案,可在移動牙齒的同時推進下顎。
While it's still very early in the adoption cycle, to-date, we're pleased with the initial uptake and expect to see continued ramp-up over the course of the year. Invisalign treatment with mandibular advancement is not available in the U.S. yet, where it's pending FDA approval.
雖然目前仍處於採用週期的非常早期階段,但截至目前我們對初期採用情況感到滿意,並預期在今年內將持續加速成長。具下顎前移功能的 Invisalign 治療目前尚未在美國上市,仍在等待 FDA 核准。
The Invisalign brand and our consumer marketing campaign programs continue to be key factors in raising awareness and creating demand for Invisalign treatment. In Q2, we continued to benefit from our investments in new programs as well as optimizing online spending and media mix for existing programs. In the U.S., we launched our new teen-focused marketing campaign in May that aims to educate teens and their parents, moms especially, about the benefits of teeth straightening with Invisalign clear aligners. It also works to ensure that teens know Invisalign treatment is the best option for their lifestyle.
Invisalign 品牌以及我們面向消費者的行銷活動方案,持續是提升認知並創造 Invisalign 治療需求的關鍵因素。第二季,我們持續受惠於對新方案的投資,以及對既有方案的線上投放與媒體組合的最佳化。在美國,我們於 5 月推出新的青少年導向行銷活動,旨在向青少年及其父母(尤其是母親)宣導使用 Invisalign 透明牙套進行牙齒矯正的益處。該活動也致力於讓青少年了解 Invisalign 治療是最符合其生活型態的最佳選擇。
The new program contributed significant growth in consumer demand during the quarter that helped drive Invisalign teen volume. Our teen campaign expands with Invisalign Made to Move campaign that we introduced in March, and we continue to see positive impact from the overarching campaign on consumer interest as well.
這項新方案在本季帶來顯著的消費者需求成長,進而推動 Invisalign 青少年病例量。我們的青少年活動在 3 月推出的 Invisalign Made to Move 活動基礎上進一步擴展,而我們也持續看到整體活動對消費者興趣帶來正面影響。
Specifically in Q2, we saw 23% year-over-year increase in unique visitors to our website and achieved significant growth year-over-year in doctor locator searches. We also saw a continued uptick in adult male patients as compared to females as a result of our changing consumer targeting approach.
具體而言,在第二季,我們網站的獨立訪客數年增 23%,且醫師搜尋定位(doctor locator)查詢量亦較去年同期大幅成長。此外,隨著我們調整消費者目標族群的方式,相較於女性患者,成人男性患者也持續增加。
In EMEA, early results show the Invisalign Made to Move campaign is resulting in higher engagement with consumers across digital display, PPC and social channels. During the quarter, we piloted new social media formats that delivered exceptional results, Pinterest, Facebook Canvas and Instagram all outperforming benchmarks. Social media remains a key driver, delivering 200% more users, although we also saw a significant increase in the number of Smile Assessment completions, plus 22%; and total leads, plus 30%. And we'll continue to roll out the Made to Move campaign across the remaining countries in EMEA in Q3.
在 EMEA 地區,初步結果顯示 Invisalign「Made to Move」行銷活動正透過數位展示廣告、PPC 與社群渠道,帶來更高的消費者互動。本季我們試行了新的社群媒體格式並取得卓越成效,Pinterest、Facebook Canvas 與 Instagram 的表現皆優於基準。社群媒體仍是關鍵驅動力,帶來多 200% 的使用者;同時我們也看到「微笑評估」完成數顯著增加,成長 22%;以及總潛在客戶(leads)成長 30%。我們將在第三季於 EMEA 其餘國家持續推廣「Made to Move」活動。
In the Asia Pacific region, our Q2 customer marketing campaigns focused primarily on Australia and New Zealand, where we saw momentum from our summer campaign featuring Invisalign Ambassador John Dundas (sic) [Jason Dundas], a well-known TV host and personality in Australia. The campaign shares Jason's personal journey of how Invisalign treatment helped transform his smile and his career, along with a call to action for consumers focused on their New Year's resolution to improve their lives by getting the smile they've always wanted.
在亞太地區,我們第二季的客戶行銷活動主要聚焦於澳洲與紐西蘭;我們看到由夏季活動帶動的動能,該活動邀請 Invisalign 品牌大使 John Dundas(原文如此)[Jason Dundas],他是澳洲知名電視主持人與公眾人物。該活動分享 Jason 的個人歷程,說明 Invisalign 療程如何幫助他改變笑容與職涯,並呼籲消費者以新年新希望為出發點,透過獲得一直想要的笑容來改善生活。
We also continued driving Invisalign website doctor locator visits by reaching out to potential patients who engaged with our ads and banners in Q1. And in India, where we're just getting started, we participated in Beach Fashion Week, where the Invisalign brand was their Beautiful Smile Partner.
我們也持續透過觸及在第一季與我們廣告與橫幅互動的潛在患者,推動 Invisalign 官網的醫師查詢(doctor locator)造訪量。此外,在我們才剛起步的印度市場,我們參與了 Beach Fashion Week,Invisalign 品牌擔任其「Beautiful Smile Partner」。
In Q2, our scanner revenues increased 36.7% year-over-year and 26.9% sequentially. In May, we announced the new iTero Element 1.5 software upgrade, which includes 2 key features: TimeLapse and 1-minute scan. TimeLapse compares the patient's prior 3D scans to their most current scan and gives doctors an enhanced visualization assessment and communications tool that can help them provide additional treatment recommendations.
第二季,我們的掃描儀營收年增 36.7%,季增 26.9%。5 月,我們宣布推出新的 iTero Element 1.5 軟體升級,包含兩項關鍵功能:TimeLapse 與 1 分鐘掃描。TimeLapse 會將患者先前的 3D 掃描與最新掃描進行比較,為醫師提供更強化的視覺化評估與溝通工具,協助其提出額外的治療建議。
1-minute scans enable practitioners to complete a full arch scan in less than a minute with the same accuracy and reliability practitioners have come to expect from iTero scanners. The use of our iTero scanners for Invisalign case submission in place of PVS impressions continues to expand, remains a positive catalyst for Invisalign utilization.
1 分鐘掃描讓臨床人員能在不到 1 分鐘內完成全牙弓掃描,同時維持 iTero 掃描儀一貫的精準度與可靠性。以我們的 iTero 掃描儀取代 PVS 印模來提交 Invisalign 病例的使用持續擴大,仍是推動 Invisalign 使用量的正向催化因素。
In Q2, total Invisalign cases submitted with the digital scanner in North America increased to a record 59%, up from 47% in Q2 of last year.
第二季,北美使用數位掃描儀提交的 Invisalign 病例占比提升至創紀錄的 59%,高於去年第二季的 47%。
In the doctor-directed, at-home channel, Q2 was our second full quarter supplying clear aligners to SmileDirectClub or SDC. Q2 shipments to this new channel were strong and nearly tripled sequentially off a small base. As their exclusive third-party supplier, we produce roughly 1/3 of SmileDirectClub's clear aligner volume and they manufacture the remaining amount.
在由醫師主導的居家(at-home)通路方面,第二季是我們向 SmileDirectClub(SDC)供應透明牙套的第二個完整季度。第二季對此新通路的出貨表現強勁,並在較小基期上季增近三倍。作為其獨家第三方供應商,我們生產約三分之一的 SmileDirectClub 透明牙套量,其餘由他們自行製造。
In Q2, SDC continued to invest significantly in consumer marketing, including TV advertising, print, online media, including social media, which we believe has a positive effect on both SDC and Invisalign demand. We also opened several new SmileShops in the U.S, which are continuing to ramp.
第二季,SDC 持續大幅投入消費者行銷,包括電視廣告、平面媒體、線上媒體(含社群媒體);我們認為這對 SDC 與 Invisalign 的需求皆有正面影響。我們也在美國開設了數家新的 SmileShop,並持續放量成長。
Overall, we're excited about the long-term potential for the at-home, doctor-directed market and remain pleased with our investment and supply agreement. Today, we also announced that we have purchased an additional 2% of SmileDirectClub for $12.8 million, which brings our total ownership to 19%. We've extended SDC's line of credit from $15 million to $30 million.
整體而言,我們對由醫師主導的居家市場之長期潛力感到振奮,並持續對我們的投資與供應協議感到滿意。今天我們也宣布以 1,280 萬美元再購入 SmileDirectClub 額外 2% 股權,使我們的總持股比例達到 19%。我們已將 SDC 的信用額度由 1,500 萬美元提高至 3,000 萬美元。
Finally, before I turn the call over to John, I want to provide a brief update on our operational expansion plans.
最後,在我把電話會議交給 John 之前,我想簡要更新我們的營運擴張計畫。
In June, we opened a new treatment planning facility in Chengdu, China, which services and supports our customers within China. It also serves as a clinical education and training center for all of our customers across Asia Pacific. We have been steadily migrating Chinese Invisalign cases to Chengdu and are continuing to train new technicians and improve lead times. We will also open a treatment planning facility to support our EMEA customers in Cologne, Germany in Q3.
6 月,我們在中國成都啟用新的治療規劃中心,為中國境內客戶提供服務與支援。該中心同時也作為臨床教育與訓練中心,服務整個亞太地區的所有客戶。我們已穩步將中國的 Invisalign 病例移轉至成都,並持續訓練新技術人員與改善交付時程(lead times)。我們也將於第三季在德國科隆開設治療規劃中心,以支援 EMEA 客戶。
With that, I'll turn it over to John.
接下來,我把時間交給 John。
John F. Morici - CFO
John F. Morici - CFO
Thanks, Joe. Now for our Q2 financial results.
謝謝,Joe。接著說明我們第二季的財務結果。
Total company revenue for the second quarter was a record $356.5 million, up 14.9% from the prior quarter and up 32.3% from the corresponding quarter a year ago. Clear aligner revenue of $321 million was up 13.7% sequentially, driven by -- primarily by better-than-expected Invisalign shipments and higher Invisalign ASPs. Year-over-year, clear aligner revenue growth of 31.9% reflected strong Invisalign shipment growth across all customer channels and geographies and increased prices. This is partially offset by product mix shift to noncomprehensive products primarily driven by increased sales of SDC clear aligners, higher discounts and unfavorable foreign exchange rates.
第二季公司總營收創新高,達 3.565 億美元,較前一季成長 14.9%,較去年同期成長 32.3%。透明牙套營收 3.21 億美元,季增 13.7%,主要由優於預期的 Invisalign 出貨量與較高的 Invisalign 平均售價(ASP)所帶動。年增方面,透明牙套營收成長 31.9%,反映所有客戶通路與各地區的 Invisalign 出貨量強勁成長,以及價格上調。上述成長部分被產品組合轉向非全口(noncomprehensive)產品所抵銷,該轉變主要由 SDC 透明牙套銷售增加、更高折扣與不利匯率所致。
Q2 Invisalign ASPs were up sequentially, approximately $15 from Q1 to $1,285, reflecting price increases and favorable foreign exchange, partially offset by increased promotional discounts. On a year-over-year basis, Q2 Invisalign ASPs were flat, reflecting price increases offset by increased promotional discounts and unfavorable foreign exchange.
第二季 Invisalign 平均售價(ASP)較第一季季增約 15 美元至 1,285 美元,反映價格上調與有利匯率,但部分被促銷折扣增加所抵銷。以年增來看,第二季 Invisalign ASP 持平,反映價格上調被促銷折扣增加與不利匯率所抵銷。
For the second quarter, total Invisalign shipments of 231,900 cases were up 11.5% sequentially, driven primarily by our international doctors and North American orthodontists. Year-over-year, Invisalign case volume growth was up 31%, driven by growth across all regions as well as expansion of our customer base primarily from Asia Pacific. For North American orthodontists, Q2 Invisalign case volume was up 10.5% sequentially and up 34.5% year-over-year. For North American GP dentists, Invisalign case volume was up 9.9% sequentially and up 18.9% year-over-year. For international doctors, Invisalign case volume was up 13.6% sequentially and up 37.4% year-over-year.
第二季 Invisalign 總出貨量為 231,900 例,季增 11.5%,主要由國際醫師與北美矯正專科醫師帶動。年增方面,Invisalign 病例量成長 31%,由各區域成長以及客戶基礎擴大所驅動,其中主要來自亞太地區。就北美矯正專科醫師而言,第二季 Invisalign 病例量季增 10.5%,年增 34.5%。就北美一般牙醫(GP)而言,Invisalign 病例量季增 9.9%,年增 18.9%。就國際醫師而言,Invisalign 病例量季增 13.6%,年增 37.4%。
Our scanner and services revenue for the second quarter was $35.4 million, up 26.9% sequentially and up 36.7% year-over-year.
第二季我們的掃描儀與服務營收為 3,540 萬美元,季增 26.9%,年增 36.7%。
Moving on to gross margin. Second quarter overall gross margin was 76%, up 0.1 points sequentially and down 0.2 points year-over-year. Clear aligner gross margin for the second quarter was 78.1%, up 0.2 points sequentially primarily due to leveraging our manufacturing cost over higher volume. Clear aligner gross margins were down 0.5 points year-over-year primarily due to lower ASPs.
接著談毛利率。第二季整體毛利率為 76%,季增 0.1 個百分點,年減 0.2 個百分點。第二季透明牙套毛利率為 78.1%,季增 0.2 個百分點,主要因在較高出貨量下攤提製造成本。透明牙套毛利率年減 0.5 個百分點,主要因 ASP 較低。
Scanner gross margin for the second quarter was 56.7%, up 0.6 points sequentially primarily due to lower services cost on our installed base and partially offset by lower ASPs. Scanner segment gross margin was up 3.1 points year-over-year, primarily a result of lower service costs and product mix shift to our lower cost iTero Element scanner.
第二季掃描儀毛利率為 56.7%,季增 0.6 個百分點,主要因既有裝機基礎的服務成本降低,但部分被 ASP 較低所抵銷。掃描儀事業部毛利率年增 3.1 個百分點,主要由服務成本降低以及產品組合轉向成本較低的 iTero Element 掃描儀所致。
Q2 operating expenses were $187.3 million, up sequentially by $13.4 million or 7.7% primarily related to increased employee headcount, marketing programs, including our advertising campaigns, key customer events and international commercialization efforts. On a year-over-year basis, Q2 operating expenses were up 33.7%, reflecting increased headcount and continued investment in our go-to-market activities critical to the growth of the business.
第二季營業費用為 1.873 億美元,較前一季增加 1,340 萬美元或 7.7%,主要與員工人數增加、行銷方案(包含廣告活動)、重要客戶活動及國際商業化推進相關。以年增來看,第二季營業費用增加 33.7%,反映人力增加以及持續投資於我們的市場推進(go-to-market)活動,而這些活動對業務成長至關重要。
Our second quarter operating margin was 23.4%, up 3.5 points sequentially and down 0.8 points year-over-year. The sequential increase in operating margin relates primarily to increased clear aligner volume. On a year-over-year basis, the decrease in operating margin primarily reflects higher operating expenses as we invest in headcount, geographic expansion and new products in order to increase adoption and accelerate the growth of our business. With regards to our second quarter tax provision, our tax rate was 17.7%, which includes $1.1 million in excess tax benefits and is down by approximately 5.5 points compared to prior year primarily due to a favorable resolution of foreign jurisdiction, unrecognized tax benefits during the quarter.
我們第二季的營業利益率為 23.4%,較上一季增加 3.5 個百分點,較去年同期下降 0.8 個百分點。營業利益率的季增主要與透明牙套出貨量增加有關。以年對年來看,營業利益率下降主要反映我們為提高採用率並加速業務成長而在員工人力、地理擴張及新產品上的投資,導致營業費用較高。關於第二季的所得稅提列,我們的稅率為 17.7%,其中包含 110 萬美元的超額稅務利益,較去年同期約下降 5.5 個百分點,主要由於本季外國司法管轄區未確認稅務利益獲得有利解決。
We supply aligners to SmileDirectClub, and therefore, revenue and cost for this activity are included in our operating profit and reporting results although they were immaterial to the company this quarter. Additionally, we report our share of SmileDirectClub losses below operating margin and our tax provision and is entitled Equity in Losses of Investee, Net of Tax.
我們向 SmileDirectClub 供應牙套,因此,儘管本季對公司而言金額不重大,該活動的收入與成本仍納入我們的營業利益與申報結果。此外,我們將 SmileDirectClub 虧損中屬於我們的份額列示於營業利益率與所得稅提列之下,科目為「被投資公司虧損之權益法認列(扣除稅後)」。
Our Q2 loss, net of tax, was approximately $2.2 million or $0.03 per diluted share. Second quarter diluted earnings per share was $0.85, flat compared to Q1, and up 37% compared to prior year.
我們第二季稅後淨損約為 220 萬美元,或每股稀釋虧損 0.03 美元。第二季稀釋每股盈餘為 0.85 美元,較第一季持平,較去年同期增加 37%。
Moving on to the balance sheet. As of the second quarter, cash, cash equivalents and marketable securities, including both short and long-term investments, were $676.6 million. This compared to $644.2 million at the end of Q1, an increase of approximately $32.4 million primarily related to net income growth and our collections efforts. Of our $676.6 million of cash, cash equivalents and marketable securities, $218.4 million was held by the U.S. and $458.2 million was held by our international entities.
接著看資產負債表。截至第二季,現金、約當現金及有價證券(包含短期與長期投資)為 6.766 億美元。相較第一季末的 6.442 億美元,增加約 3,240 萬美元,主要與淨利成長及我們的收款努力有關。在 6.766 億美元的現金、約當現金及有價證券中,美國持有 2.184 億美元,海外實體持有 4.582 億美元。
Q2 accounts receivable balance was $291.7 million, up approximately 9.2% sequentially. Our overall DSO was 74 days, down 3 days sequentially and up 10 days year-over-year. The year-over-year increase is a result of our ERP and other related systems implementation last July, which have impacted our timing of our customer collections. As we work through these changes, we anticipate that our DSOs will continue to decline over the next few quarters.
第二季應收帳款餘額為 2.917 億美元,較上一季約增加 9.2%。整體 DSO(應收帳款週轉天數)為 74 天,較上一季減少 3 天,較去年同期增加 10 天。年對年增加是因去年 7 月我們導入 ERP 及其他相關系統,影響了客戶收款時點。隨著我們逐步消化這些變更,我們預期未來幾季 DSO 將持續下降。
Cash flow from operations for the second quarter was $110.5 million, up $34.3 million compared to prior year. Free cash flow for the second quarter, defined as cash flow from operations less capital expenditures, amounted to $92 million. Capital expenditures for the second quarter were $18.5 million, primarily relating to building improvements, equipment purchases for additional manufacturing capacity as well as our global expansion efforts.
第二季營運活動現金流量為 1.105 億美元,較去年同期增加 3,430 萬美元。第二季自由現金流量(定義為營運活動現金流量減資本支出)為 9,200 萬美元。第二季資本支出為 1,850 萬美元,主要用於廠房改善、為增加製造產能而購置設備,以及我們的全球擴張工作。
During the second quarter, we paid $50 million under an accelerated stock repurchase plan, ASR, in which we received an initial delivery of approximately 300,000 shares of common stock. The final number of shares repurchased will be determined at the completion of the ASR based on Align's volume-weighted average stock price during the term of the ASR, less than agreed-upon discounts.
第二季期間,我們在加速股票回購計畫(ASR)下支付 5,000 萬美元,並收到約 30 萬股普通股的初始交付。最終回購股數將於 ASR 完成時決定,依據 ASR 期間 Align 的成交量加權平均股價,並扣除事先約定的折扣。
There remains approximately $250 million available for repurchases under the existing stock repurchase authorization. And as Joe mentioned earlier, we have purchased an additional 2% of SmileDirectClub for $12.8 million, which brings our total ownership to 19%, and we extended SDC's line of credit from $15 million to $30 million. All other terms remain the same.
在現有股票回購授權下,仍有約 2.5 億美元可用於回購。另外,如 Joe 先前提到,我們以 1,280 萬美元再購入 SmileDirectClub 額外 2% 股權,使我們的總持股提升至 19%,並將 SDC 的信用額度由 1,500 萬美元延長至 3,000 萬美元。其他條款維持不變。
With that, let's turn to our Q3 outlook and the factors that inform our view, starting with the demand outlook. For our international markets, expect Invisalign volume to be up sequentially, which reflects continued strong growth in APAC, partially offset by summer holidays in EMEA.
接下來,我們來看第三季展望以及支撐我們看法的因素,先從需求展望開始。在國際市場方面,預期 Invisalign 出貨量將較上一季增加,反映亞太地區(APAC)持續強勁成長,但部分被歐洲、中東與非洲(EMEA)的暑期假期所抵銷。
For North America, expect Invisalign volume to be flat to slightly down sequentially, reflecting stronger teen volume for orthos, offset by GP dentists who typically have less days in the office and lighter patient traffic during the summer. For our scanner business, we expect revenues to be up sequentially.
在北美方面,預期 Invisalign 出貨量將較上一季持平至小幅下降,反映矯正專科(ortho)的青少年病例量較強,但被一般牙醫(GP)在夏季通常門診天數較少、病患來診量較低所抵銷。在掃描儀業務方面,我們預期營收將較上一季增加。
With this as a backdrop, we expect the third quarter to shape up as follows: Invisalign case volume is expected to be in the range of 231,000 to 234,000 cases, up approximately 30% to 32% over the same period a year ago, reflecting continued strong demand, including summer seasonality in North America ortho and Asia Pacific. We expect Q3 net revenues to be in the range of $355 million to $360 million, an increase of 27% to 29% year-over-year. We expect Q3 gross margins to be in the range of 74.7% to 75.7%, reflecting higher ASPs partially offset by higher expenses as we globalize our treatment planning operations.
在此背景下,我們預期第三季表現如下:Invisalign 病例量預計介於 231,000 至 234,000 例,較去年同期約增加 30% 至 32%,反映需求持續強勁,並包含北美矯正專科與亞太地區的夏季季節性因素。我們預期第三季淨營收介於 3.55 億至 3.60 億美元,年對年增加 27% 至 29%。我們預期第三季毛利率介於 74.7% 至 75.7%,反映較高的平均售價(ASP),但部分被我們推動治療計畫作業全球化所帶來的較高費用所抵銷。
We expect Q3 operating expenses to be in the range of $184.5 million to $187.5 million, relatively flat on a sequential basis. Q3 operating margin should be in the range of 22.7% to 23.6%. Our effective tax rate, including an excess tax benefit of about $1 million, should be approximately 21%.
我們預期第三季營業費用介於 1.845 億至 1.875 億美元,季對季大致持平。第三季營業利益率應介於 22.7% 至 23.6%。我們的有效稅率(包含約 100 萬美元的超額稅務利益)應約為 21%。
We expect a $2 million loss related to our share of SmileDirectClub, and diluted shares outstanding should be approximately 81.8 million, exclusive of any share repurchases.
我們預期與我們分攤 SmileDirectClub 的份額相關將有 200 萬美元的損失,而稀釋流通在外股數約為 8,180 萬股,不包含任何股票回購的影響。
Taken together, we expect our Q3 diluted earnings per share to be in the range of $0.78 to $0.81. In addition, as we continue to operationalize expansion efforts, we expect CapEx for Q3 to be approximately $70 million to $75 million, which includes purchasing a new facility in Costa Rica for $26.1 million.
綜合以上,我們預期第三季稀釋每股盈餘介於 0.78 至 0.81 美元。此外,隨著我們持續推動擴張工作落地執行,我們預期第三季資本支出約為 7,000 萬至 7,500 萬美元,其中包含以 2,610 萬美元在哥斯大黎加購置一處新設施。
With that, I'll turn it back over to Joe for final comments. Joe?
接下來,我把時間交還給 Joe 做最後的補充。Joe?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Thanks, John. Overall, we're pleased to see the first half of the year off to such a strong start. Many of you have already recently -- think of a question about us being at a tipping point, and I'm sure we'll get that question following today's call.
謝謝,John。整體而言,我們很高興看到今年上半年有如此強勁的開局。你們許多人最近已經——想必都在思考我們是否正處於一個臨界點的問題,我相信在今天的電話會議之後我們也會收到這個問題。
Frankly, we think it's too early to tell. The growth we're seeing in our business is better than we expected and reflects progress in several areas, including clinical efficacy, sales coverage and support models, customer engagement and demand generation and patient capture. We believe it also reflects a healthy underlying market with solid patient traffic and a significant increase in direct-to-consumer programs by us and others.
坦白說,我們認為現在下結論還太早。我們在業務上看到的成長優於預期,並反映我們在多個面向的進展,包括臨床療效、銷售覆蓋與支援模式、客戶互動與需求創造,以及病患導入。我們也相信,這反映了健康的基本市場環境:病患來診量穩健,且我們與其他業者的直面消費者(DTC)方案顯著增加。
There is still a lot of work ahead as we move toward our goal of replacing metal braces and making Invisalign the standard of care in orthodontics. We know there will be challenges. We aren't drawing a straight line up and to the right at this point, but we are confident in our ability to drive this industry forward and transform it from an outdated analog process to a fully digital system.
在我們邁向以 Invisalign 取代金屬牙套、並使其成為齒顎矯正標準治療的目標過程中,前方仍有大量工作要做。我們知道會有挑戰。此刻我們不會畫出一條一路向上、向右的直線,但我們對推動這個產業向前、並將其從過時的類比流程轉型為完全數位化系統的能力充滿信心。
Thanks for your time today, and we look forward to your questions.
感謝各位今天撥冗參與,我們期待你們的提問。
Operator
Operator
(Operator Instructions) Our first question comes from the line of Robert Jones of Goldman Sachs.
(接線員指示) 我們的第一個問題來自高盛(Goldman Sachs)的 Robert Jones。
Robert Patrick Jones - VP
Robert Patrick Jones - VP
Joe, the teen growth for the past couple of quarters now, the acceleration has been noticeably pretty steep. Understanding that it's obviously not one factor that's driving its acceleration, is there any couple of areas that you would point to specifically, anything that you could just help us get our head around what you think is most resonating with practitioners in the marketplace?
Joe,過去幾個季度青少年業務的成長,增速明顯相當陡峭。理解這顯然不是單一因素在推動加速,但你是否能特別指出幾個領域,幫助我們理解你認為在市場上最能引起臨床醫師共鳴的是什麼?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Bob, from a teen standpoint, overall, I'd just focus on North America for a second. We mentioned last year when we put our plan together that we would have a strong focus on teens as we go into the second quarter this year because this is the teen season for North America. What we started that program off was we had several programs in North America just to get doctors ready for this program: overall, next-level partnership, a program we call IMOP (sic) [IOMP], some specific things that really focused on teens to get that base ready. And then we started to really unleash the communications part of this, the $14 million or so that we're moving in consumer advertising to do that. So I think when you look at first half and those 2 kind of simultaneous actions, that's been really one of the biggest underlying drivers in North America to make that, to really go.
Bob,從青少年這一塊來看,整體而言我先聚焦北美。我們去年在制定計畫時提到,進入今年第二季我們會強力聚焦青少年,因為這是北美的青少年旺季。我們啟動該計畫時,在北美做了幾個專案,先讓醫師為這個計畫做好準備:整體的 next-level partnership、我們稱為 IMOP(原文如此)[IOMP] 的專案,以及一些真正聚焦青少年的具體措施,先把基礎打好。接著我們開始真正釋放這部分的溝通/傳播力道,也就是我們把約 1,400 萬美元轉到消費者廣告上來推動。所以我認為,當你看上半年以及這兩項幾乎同步的行動時,這一直是北美最主要的底層驅動因素之一,讓它真正跑起來。
So that along with our ad campaigns and everything else we put in place that are much more specific these days in the sense of how we go to market, you see how we're working both the teen channels and the moms channels from a marketing standpoint also. It's just a much cleaner, more specific approach to teens that includes a real sales effort with our doctors and a real strong customer or patient-facing piece with moms and teens.
因此,這再加上我們的廣告活動以及我們所部署的其他措施——就我們如今的上市策略而言更具針對性——你也看到從行銷角度,我們同時在經營青少年通路與媽媽通路。這是一個更乾淨、更明確的青少年策略:包含與醫師端的實質銷售投入,以及面向媽媽與青少年的強力客戶/患者端溝通。
Robert Patrick Jones - VP
Robert Patrick Jones - VP
I appreciate all that. And then I guess just shifting over, I had a question on North American GPs and then the focus has been on orthos and rightfully so. But notice that the North American GP saw a significant step-up from the level of growth you had been seeing. Anything that you would talk to there specifically that you think would attribute to the step-up in growth we saw in the quarter?
我很感謝這些說明。接著我想換個話題,我有一個關於北美 GP(一般牙醫)的問題,大家的焦點一直放在正畸醫師(orthos)上,這也很合理。但我注意到北美 GP 的成長相較你們先前的成長水準有明顯跳升。你是否能具體談談,你認為本季看到的成長跳升可歸因於哪些因素?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Yes, I'd say 2 major variables, Bob. One would be just media spend. We've had a significant increase in media spend itself and we have seen a strong correlation between media spend in the U.S. and GP increase. And then secondly, like on the Lite product that we introduced in the second quarter with the GP segment, we're more and more targeting that segment with easier products that are more simple for them to deliver to the marketplace. So I think media spend in some specific products have really helped in that sense.
是的,Bob,我會說有兩個主要變數。第一個是媒體投放。我們的媒體投放本身大幅增加,而且我們看到美國媒體投放與 GP 成長之間有很強的相關性。第二個是我們在第二季針對 GP 族群推出的 Lite 產品,我們愈來愈多地以更容易、對他們而言更簡單、能更容易交付到市場的產品來鎖定這個族群。所以我認為媒體投放加上一些特定產品,在這方面確實帶來很大幫助。
Operator
Operator
Our next question comes from the line of Brandon Couillard of Jefferies.
我們的下一個問題來自 Jefferies 的 Brandon Couillard。
Samuel Brandon Couillard - Equity Analyst
Samuel Brandon Couillard - Equity Analyst
Joe, on SmileDirectClub, could you give us the -- a sense of how much of the manufacturing volume you did for them in the first quarter? And I'm just curious like why the equity -- the additional equity investment couldn't have been larger and if that was even an option for you guys.
Joe,關於 SmileDirectClub,你能否讓我們了解一下第一季你們為他們承接了多少製造量?另外我也好奇,為什麼股權——額外的股權投資——不能更大?以及這對你們來說是否曾是一個選項?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Well, we mentioned in my briefing that we're doing 1/3 of their cases right now. It's still not material in that sense, Brandon. We just wanted to give you just an idea of where we stand overall. They do still 2/3 of their volume. As far as the percent equity, it was just an opportunity we have; we work closely with David and his team at SDC. And that equity was available. We're pleased with the relationship, and we thought that was just a great next step for us in that sense.
嗯,我在簡報中提到,我們目前承作他們約 1/3 的案例。就這個意義上來說,Brandon,它仍然不算重大。我們只是想讓你大概了解我們整體所處的位置。他們仍然自行處理約 2/3 的量。至於持股比例,那只是我們的一個機會;我們與 SDC 的 David 及其團隊密切合作。而那部分股權是可取得的。我們對這段合作關係感到滿意,也認為這是我們在這方面很好的下一步。
Samuel Brandon Couillard - Equity Analyst
Samuel Brandon Couillard - Equity Analyst
Then on teen, I'm curious if the second quarter was materially ahead of where you thought it would be in terms of volumes. And then would it be reasonable to expect further acceleration in the teen growth rate in the third quarter given that the ad campaign didn't really start until mid-2Q?
再回到青少年,我好奇第二季的量是否實質上高於你們原先的預期。另外,考量廣告活動直到第二季中段才真正開始,是否可以合理預期第三季青少年成長率會進一步加速?
John F. Morici - CFO
John F. Morici - CFO
Yes, I'll take that one. Brandon, this is John. The -- what we saw with teens that helped us contribute to some of the upside that we saw in the second quarter for some of the volume and it's part of the overall campaign that we have, where we're spending additional this year. And our guidance in Q3 reflects all those factors into our numbers.
是的,這題我來回答。Brandon,我是 John。我們在青少年方面看到的表現,確實幫助我們在第二季的部分出貨量上帶來一些超預期的上行,這也是我們整體行銷活動的一部分——今年我們在這方面增加了支出。而我們對第三季的財測指引,已把所有這些因素反映在數字裡。
Samuel Brandon Couillard - Equity Analyst
Samuel Brandon Couillard - Equity Analyst
And then the $14 million for the ad campaign, was that all absorbed in 2Q? Or is there some that rolls into the third quarter as well?
那麼這 1,400 萬美元的廣告活動費用,是在第二季就全部吸收了嗎?還是也有一部分會延續到第三季?
John F. Morici - CFO
John F. Morici - CFO
That's throughout the year. I mean, it's primarily where a lot of that hits in the second and third quarter but it's -- there's additional spend throughout the year.
這是分散在全年。我的意思是,其中很大一部分主要會落在第二季和第三季,但——全年都還會有額外支出。
Operator
Operator
Our next question comes from the line of John Kreger of William Blair.
我們的下一個問題來自 William Blair 的 John Kreger。
John Charles Kreger - Partner and Healthcare Services Analyst
John Charles Kreger - Partner and Healthcare Services Analyst
Another just quick follow-up on SmileDirect. When you did the deal, I think you said that when incoming case volume came in, if the case was too complicated, it would sort of get pushed into Invisalign. Is that the case? And if so, what have you learned? What sort of percentage of case volume ends up driving into Invisalign?
再針對 SmileDirect 做個快速追問。你們做這筆交易時,我記得你們說過,當進來的案例量如果太複雜,就會被導入 Invisalign。現在仍是如此嗎?如果是,你們學到了什麼?大概有多少比例的案例量最後會導入 Invisalign?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
We haven't had -- John, it's Joe. We haven't had terrific conversion rates in that sense, but we've learned a lot and we tweak that model all the time.
我們——John,我是 Joe。就這個意義上來說,我們的轉換率並不算特別理想,但我們學到了很多,也一直在調整那個模式。
The patients at SmileDirectClub's service, they have a certain price point in mind. They usually have a simple kind of an approach that they want in the sense of correcting their smile, and they need to be dealt with really quickly. In other words, when those patients are interested, moving them into an orthodontist in this case or a GP that wants to do that, it has to be done quickly and concisely. These patients are -- they're just different than the normal patients that we work with. So we keep honing that model. We've had some success, and we keep building on it. But we think in the future, as we put this thing together, we'll have a much better yield.
使用 SmileDirectClub 服務的患者,他們心中有一個特定的價格帶。他們通常希望以相對簡單的方式來矯正笑容,而且需要非常快速地被服務。換句話說,當這些患者有興趣時,要把他們導入正畸醫師(在這個案例中)或願意承作的一般牙醫(GP),必須快速且精準地完成。這些患者——他們和我們平常服務的典型患者不太一樣。所以我們持續打磨這個模式。我們已經有一些成功案例,也會持續在此基礎上擴大。但我們認為未來,隨著我們把這件事整合得更完善,產出/轉換效率會好很多。
John Charles Kreger - Partner and Healthcare Services Analyst
John Charles Kreger - Partner and Healthcare Services Analyst
Great. And Joe, I think you said you're just getting started on India. Can you talk a little bit more about that market, maybe try to size it for us and just kind of lay out what sort of strategy you're thinking about to ramp it over time?
很好。Joe,我想你說你們在印度才剛開始。你能多談談那個市場嗎?也許幫我們估算一下規模,並大致說明你們打算如何制定策略、隨時間逐步拉升?
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
Oh, India. You said India, John?
喔,印度。你是說印度,John?
John Charles Kreger - Partner and Healthcare Services Analyst
John Charles Kreger - Partner and Healthcare Services Analyst
Yes, India.
是的,印度。
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Oh, India. Oh, that's India. I would go back in India again this year -- just there last year. What we do when we go into a country like that, John, is we -- you really do this by city. When you go in the city and you recruit doctors and you just begin to ramp up in those specific cities, you find great doctors in a sense of peer-to-peer being able to -- one doctor teach another. And so you look at this as almost a city-by-city effort in India. We'll take, obviously, the biggest and most prosperous cities first and we work out from there.
喔,印度。喔,那是印度。我今年會再去印度——去年才剛去過。John,我們進入那樣的國家時,我們——基本上是以城市為單位來做。當你進入一個城市、招募醫師,並開始在那些特定城市逐步拉升時,你會找到很棒的醫師,能以同儕對同儕的方式——一位醫師教另一位醫師。因此在印度,你幾乎可以把它視為逐城推進的工作。我們當然會先從最大、最富裕的城市開始,然後再由此向外擴展。
We're really in our second year of this in a big way. We're reaching our goals. The business has been growing pretty rapidly in that sense. And this is a model we really follow all over the world. It's just when you get to India, you just have to make sure that you approach it in an Indian way. And as an example, what's an Indian way is they often don't want to buy our scanners. So what we have is a scanner that's often -- a few of them in a city on a truck that they just -- they rent. And we're moving in almost daily into different offices. They line up patients to do scans. And so we just acclimatize, to use that word, to the marketplace and keep working that. So we're excited about it, and we feel very confident of our long-term trend there.
我們確實正以很大的規模進入第二年。我們正在達成我們的目標。從這個角度來看,業務成長相當快速。而這是我們在全球各地都遵循的模式。只是當你到印度時,你必須確保以印度的方式來推進。舉例來說,所謂的印度方式是,他們往往不想購買我們的掃描儀。因此我們的做法是,通常會有一台掃描儀——或幾台——放在卡車上在城市裡運行,他們只是——用租的。我們幾乎每天都會移動到不同的診所。他們會把病患排好隊來做掃描。所以我們就用這個詞來說,就是讓自己適應市場,並持續推進。因此我們對此感到興奮,也對那裡的長期趨勢非常有信心。
Operator
Operator
Our next question comes from the line of Erin Wright of Credit Suisse.
我們的下一個問題來自 Credit Suisse 的 Erin Wright。
Adam Krasner - Equity Research Associate
Adam Krasner - Equity Research Associate
This is Adam Krasner on for Erin. I just wanted to touch on the strength in doctors trained in the quarter. I'm trying to get a sense of what the typical ramp is for new doctors who are added to get up towards the average level of productivity.
我是代替 Erin 的 Adam Krasner。我想稍微談一下本季受訓醫師人數的強勁表現。我想了解一下,新加入的醫師通常需要多長的爬坡期,才能提升到平均的生產力水準。
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
The average ramp of a new doctor, is that...
新醫師的平均爬坡期,是……
Adam Krasner - Equity Research Associate
Adam Krasner - Equity Research Associate
Right, like that probably didn't contribute very much to the record shipments in the quarter, the fact that you added so many new doctors. Or did it?
對,就像這可能對本季創紀錄的出貨量貢獻不大,因為你們新增了這麼多新醫師。還是其實有貢獻?
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
So where we're having a lot of expansion opportunities, obviously, outside the U.S. we're adding new doctors. So you're seeing a lot of the growth outside the U.S. being driven by adding new doctors. In the U.S. and, in particular, in both our ortho and GP channels, you're seeing growth by utilization predominantly. But we saw both as a driver in the GP channel.
所以我們有很多擴張機會的地方,顯然是在美國以外,我們正在新增新醫師。因此你會看到,美國以外的許多成長是由新增新醫師所帶動。在美國,尤其是在我們的矯正(ortho)與一般牙科(GP)兩個通路,你看到的成長主要是由使用量提升所驅動。但在 GP 通路,我們看到兩者都是驅動因素。
Adam Krasner - Equity Research Associate
Adam Krasner - Equity Research Associate
And do you have a sense of -- I'm looking at the statistic in the press release of 123,000 doctors trained worldwide. Is there a sense for what the total size of that market is to get a flavor of kind of how far the penetration is as of now?
那你是否能大致說明——我看到新聞稿中的統計是全球已訓練 123,000 名醫師。能否談談這個市場的總規模,讓我們了解目前的滲透率大概到什麼程度?
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
Yes. So when you look at the total size of the number of orthodontists and general dentists -- and we can follow up with you if you want more details. In the U.S., there's roughly 140,000, 150,000 GPs; and orthodontists, roughly 10,000. Outside the U.S., the market is substantially larger. In Europe, there's probably 300,000. In Asia Pacific, there's probably twice that, so very, very -- yes, it's huge, 4 or 5x that. So -- and we're happy to provide more stats for you offline.
可以。當你看矯正專科醫師與一般牙醫的總數——如果你想要更多細節,我們也可以再跟進提供。在美國,一般牙醫(GP)大約有 140,000 到 150,000 人;矯正專科醫師大約 10,000 人。美國以外的市場規模大得多。在歐洲大概有 300,000 人。在亞太地區大概是其兩倍,所以非常、非常——是的,非常龐大,大約是那個的 4 到 5 倍。所以——我們也很樂意在會後再提供更多統計資料給你。
Operator
Operator
Our next question comes from the line of Steven Valiquette of Bank of America Merrill Lynch.
我們的下一個問題來自美國銀行美林(Bank of America Merrill Lynch)的 Steven Valiquette。
Steven J. James Valiquette - MD
Steven J. James Valiquette - MD
Incredible results. So as we've been doing work and just talking to more practitioners, we're getting even greater appreciation for the SmartTrack aligner material. And I guess that the disclosure back in May that you got the 2 patents issued, just curious to get more color around the patent protection on that material because I think it is a critical part of the overall picture. I mean, the biggest thing is these seem to be the primary patents to protect that material. I just want to confirm that. And then one was filed in 2012, the other one in '16, but really -- I guess what I care about more than anything else is what's the expiration dates. How long will you get protection on this material? Is it 20 years from the date of filing or 20 years from date of issuance? I just forgot the details around that.
成果令人驚艷。所以當我們在做研究、並與更多臨床醫師交流時,我們對 SmartTrack 隱形牙套材料的認識與重視程度更高了。我想回到你們在 5 月披露已取得 2 項專利核發這件事,我想更了解該材料的專利保護情況,因為我認為這是整體圖景中非常關鍵的一部分。我的重點是,這些看起來是保護該材料的主要專利。我想確認一下是否如此。另外,一件是 2012 年申請,另一件是 2016 年申請,但其實——我最在意的是到期日是什麼時候。你們對這個材料能獲得多長時間的保護?是自申請日起 20 年,還是自核發日起 20 年?我有點忘了這部分的細節。
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Steve, it's Joe. Date of filing is 20 years. There's a multilayer material. Yes, we do have patent protection on it now. The vendor that we use on it has a certain amount of restrictions in the sense of dentistry and where it can be used but also has patents on process and all and how this is put together, not an easy material to do in that way. So yes, I mean, just look at it as from date of filing and all, we have a significant number of years that the SmartTrack continues to be an Invisalign "end of the line" material.
Steve,我是 Joe。是自申請日起算 20 年。這是一種多層材料。是的,我們現在確實對它有專利保護。我們使用的供應商在牙科領域及其可使用範圍方面有一定限制,同時也對製程等擁有專利,以及這種材料如何組合而成;以那種方式製作並不容易。所以是的,我的意思是,把它視為自申請日起算,我們還有相當多年的時間,SmartTrack 仍將是 Invisalign 的「終端」材料。
Steven J. James Valiquette - MD
Steven J. James Valiquette - MD
So on the simple math, you should be good until about 2032 or so. Is that -- am I right?
所以用簡單的數學來算,你們應該可以一路到大約 2032 年左右都沒問題。我這樣理解對嗎?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Yes, we'll both be on a beach by then. So...
是的,到那時我們兩個都會在海灘上了。所以……
Steven J. James Valiquette - MD
Steven J. James Valiquette - MD
Okay. I just want to confirm that.
好的。我只是想確認一下。
Operator
Operator
Our next question comes from the line of Jon Block of Stifel.
我們的下一個問題來自 Stifel 的 Jon Block。
Jonathan D. Block - MD and Analyst
Jonathan D. Block - MD and Analyst
Joe, you'll be on the beach and I still think I'll be at this desk right here. But maybe just some thoughts on 2017. And maybe I missed that, John, from your commentary or even the slides. But I think the last quarter, you talked about the high end of the 15% to 25% revenue growth and op margin in or around 23%. Are there revisions to either of those numbers that you gave last call for 2017?
Joe,你會在海灘上,而我覺得我還會坐在這張桌子前。不過想請教一下你們對 2017 年的一些看法。也許我漏聽了,John,可能在你的評論或投影片裡。但我記得上一季你們談到營收成長 15% 到 25% 的區間上緣,以及營業利益率大約在 23% 左右。你們對上次電話會議給出的 2017 年這兩個數字,有沒有任何修正?
John F. Morici - CFO
John F. Morici - CFO
Well, what we've guided to Q3 -- and you could see those -- that from an overall guidance standpoint. So that's the update, Jon, that we have after we've seen Q2. And then from there, you can probably do the math to kind of get -- to get overall from a year standpoint. But at least for the Q3 guide, we feel comfortable with what we've -- what we're seeing so far. And that's what we ended up forecasting.
嗯,我們已經對第三季(Q3)給出指引——你也可以看到那些——就整體指引而言。所以那就是更新,Jon,是我們在看到第二季(Q2)之後所做的更新。接下來,你大概可以自己推算,從年度角度來看整體會是什麼樣子。但至少就 Q3 的指引而言,我們對目前看到的情況感到放心。而那就是我們最後所做的預測。
Jonathan D. Block - MD and Analyst
Jonathan D. Block - MD and Analyst
Okay, I mean, I got it. I got it from a math perspective. I guess just to push you a little bit, notably on the revenue, you blow out 2, 3 -- I'm sorry, you blow out 2Q. You guide 3Q ahead. Obviously, if you just keep the 25% for the year, it would imply a bigger step-down for 4Q. But I guess you're just sort of saying, "Go with what you guys gave last quarter. There's no official change to those numbers?"
好的,我是說,我懂了。從數學角度我懂了。我想再追問一下,特別是營收方面,你們第二季表現大幅超出——抱歉,你們第二季大幅超出預期。你們把第三季指引往上調。顯然,如果你們全年仍維持 25%,那會意味著第四季會有更大的下滑幅度。但我猜你們只是想說:「就沿用你們上季給的數字。」也就是說,這些數字沒有正式變更?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
That's exactly what you're hearing, Jon.
Jon,你聽到的正是這個意思。
Jonathan D. Block - MD and Analyst
Jonathan D. Block - MD and Analyst
Okay, fair enough, fair enough.
好的,明白,明白。
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
You said it better than we wanted to. It was really good.
你說得比我們原本想說的還要好。真的很棒。
Jonathan D. Block - MD and Analyst
Jonathan D. Block - MD and Analyst
All right. And then just any thoughts on the ASP? John, if you can remind us, I believe you took price in the U.S. earlier in the year. Did you take price internationally more recently? And then the euro, for the first time in several quarters, have sort of flipped and should be a tailwind. So maybe when you think out on the Invisalign ASP in the back half of '17, is there any direction you can give us there?
好的。接著想請教一下 ASP(平均銷售單價)方面有沒有什麼看法?John,如果你能幫我們回顧一下,我記得你們今年稍早在美國調漲過價格。那國際市場是否在更近期也有調價?另外,歐元在好幾個季度以來第一次算是反轉,應該會成為順風。所以當你們展望 2017 年下半年 Invisalign 的 ASP 時,有沒有任何方向可以提供?
John F. Morici - CFO
John F. Morici - CFO
Yes, you're right, Jon. In North America, we took a price increase in April. And in EMEA, it came in July. So the price increases have happened. And as we look at what's happening for the next quarter, we're pretty much expecting price to be flat to this quarter. So we have price increases. We also have other pressures and FX unfavorability as well. But you net all that out in the third quarter, we expect ASPs to be flat.
是的,Jon,你說得沒錯。在北美,我們在 4 月做了價格調漲。在 EMEA(歐洲、中東及非洲),則是在 7 月。所以價格調漲都已經發生了。而就下一季的情況來看,我們大致預期價格相較本季會持平。因此我們有價格調漲。同時也有其他壓力以及匯率不利因素。但把這些因素在第三季加總抵銷後,我們預期 ASP 會持平。
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Jon, Joe again on your question on third quarter, fourth quarter. So I think the best way to take what we're saying is we're not calling a step-down in the fourth quarter, we're just doing -- giving you good clarity on what the third quarter is because that's where we have clarity on now and...
Jon,針對你第三季、第四季的問題,我是 Joe 再補充一下。我認為理解我們說法的最佳方式是:我們並不是在預告第四季會出現下滑(step-down),我們只是——就第三季提供更清楚的能見度,因為目前我們對第三季的能見度最高,而且……
Jonathan D. Block - MD and Analyst
Jonathan D. Block - MD and Analyst
Understood.
了解。
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Okay?
好嗎?
Jonathan D. Block - MD and Analyst
Jonathan D. Block - MD and Analyst
Understood.
了解。
Operator
Operator
Our next question comes from the line of Jeff Johnson of Robert W. Baird.
下一個問題來自 Robert W. Baird 的 Jeff Johnson。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Just on the ASPs, Jon's question just reminded me, he was asking about euro flipping and then maybe getting a little benefit over the next few quarters. John, as we get into -- as we get into '18, are we inching closer at all to any release of those additional aligner reserves, where that could theoretically start to help ASPs at all? Or is it still too early for thinking about any ASP benefit from those kind of factors?
關於 ASP,Jon 的問題提醒了我:他在問歐元反轉,接下來幾季可能會帶來一些好處。John,當我們進入 2018 年時,我們是否在任何程度上更接近釋放那些額外的矯正器(aligner)備抵(reserves),理論上可能開始對 ASP 有些幫助?還是說現在要去思考這類因素對 ASP 的助益仍然太早?
John F. Morici - CFO
John F. Morici - CFO
Yes, Jeff, it's too early. I mean, that's -- it's part of our overall plan, what we have, that premium-priced product that has the additional aligners. And that's built into the plans that we have and the pricing that we have. So there's no extra reserve coming back related to that. It's just part of our overall plan from a strategic standpoint as well as what we're thinking from an ASP standpoint.
是的,Jeff,現在還太早。我的意思是——那是我們整體計畫的一部分:我們有一個高單價的產品,包含額外的矯正器。而這已經反映在我們的計畫與定價之中。所以不會有任何與此相關的額外備抵回沖(reserve coming back)。這只是我們從策略面以及 ASP 規劃面所思考的整體方案的一部分。
Jeffrey D. Johnson - Senior Research Analyst
Jeffrey D. Johnson - Senior Research Analyst
Yes, fair enough. And Joe, I found your comments interesting at the very end of the call, just maybe a note of caution. And obviously, I know as the numbers go up, so too do expectations. And so I get trying to keep everybody kind of a little levelheaded here. But I think in past calls, you've also talked about your confidence in clear aligners eventually replacing brackets and bands and why would you want metal on your teeth and things like that. You had a slightly different message this evening. Is there anything looming over the next few quarters that has you maybe a little worried or you're just wanted to make sure we all kind of account for or titrate in our models, anything like that?
好的,合理。另外,Joe,我覺得你在電話會議最後的評論很有意思,聽起來像是稍微提醒要謹慎一點。當然我知道,數字越往上,市場期待也會跟著提高。所以我理解你想讓大家保持比較理性。但我記得你在過去的電話會議也談過,你很有信心透明矯正器最終會取代傳統托槽與鋼線,畢竟誰會想在牙齒上裝金屬之類的。但你今晚的訊息稍微不太一樣。未來幾季是否有任何事情讓你有點擔心?或者你只是希望我們在模型裡把某些因素納入、做一些調整(titrate),之類的?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
No, I'm not trying to give you any kind of warning or anything like that, Jeff. I have all the confidence in the world, like I said in my final comments, that we'll complete this mission of eliminating wires and brackets with a digital system with plastic. Just, I think -- I get questions all the time, as you can guess and you see this kind of growth rates about the -- are we in a tipping point in this business. And I think we all know about the whole term tipping point and what it would mean. And all I was trying to get across is I don't think you can take 2 quarters and draw a line through the tipping point. But don't mistake in anything at all that there is something that we see that would, in some way, shake our confidence in what we think we can do.
不,Jeff,我不是要給你任何警訊或類似的意思。正如我在最後的評論所說,我對我們完成這個使命——用數位系統與塑料材料來消除鋼線與托槽——有十足的信心。只是我想——你可以想像,我經常被問到,看到這樣的成長率,大家會問我們這個產業是不是到了所謂的「臨界點」(tipping point)。而我們都知道「臨界點」這個詞以及它代表的意義。我只是想表達:你不能只用兩個季度就畫一條線,然後說已經到了臨界點。但也請不要誤會,我們並沒有看到任何會在某種程度上動搖我們對自身能力與方向的信心的事情。
Operator
Operator
Our next question comes from the line of Richard Newitter of Leerink Partners.
下一個問題來自 Leerink Partners 的 Richard Newitter。
Ravi Misra - Associate
Ravi Misra - Associate
It's actually Ravi in for Rich. So just a couple, if I can start just with the scanner business. You guided -- I think I heard up sequentially 3Q. Can you give us a little bit of color in terms of what kind of penetration into your adoption base are you seeing here? I mean, if we use a proxy of about 34,000 doctors that you shipped Invisalign product to last year, can you help us kind of understand what the runway here is for additional docs taking -- picking up this product? And then secondly, I'm just going to take a stab at the SDC volume. I'm guessing maybe about 2,000 cases in the quarter. Any direction on that?
其實我是代替 Rich 的 Ravi。我有幾個問題,先從掃描器(scanner)業務開始。你們的指引——我想我聽到的是第三季會季增。能否提供一些背景,說明你們在既有採用客群中的滲透率大概到什麼程度?如果我們用一個代理指標:去年你們出貨 Invisalign 產品的醫師大約 34,000 位,你能否幫我們理解未來還有多少空間讓更多醫師採用、開始購買這個產品?第二個,我想試著猜一下 SDC 的量。我猜本季可能大約 2,000 個案例(cases)。你們能否給一些方向?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Ravi, on the scanner penetration, you have to look at it as almost 2 separate markets, the orthodontic market and the GP market. I'm not sure exactly how far penetrative we are in the orthodontic side, but let's say what you have to look at is often, when a doctor starts to do more and more Invisalign, they want an iTero scanner per chair. And so you really can't look at it as a unit per doctor in that sense. You've got to look at it as a unit in a sense of number of chairs in that office. And so I'd say, obviously, we have a higher penetration right now on the ortho side than we do on the GP side. But what -- like rate Shirley quoted a moment ago, the 150,000 GPs in the United States, we haven't really even begun in that sense. And that type of scanner has a good balance between Invisalign and being able to do restorative applications, too.
Ravi,關於掃描器的滲透率,你得把它視為幾乎是兩個不同市場:矯正專科(orthodontic)市場與一般牙科(GP)市場。我不確定我們在矯正專科端的滲透到底有多深,但你要這樣看:通常當一位醫師開始做越來越多 Invisalign,他們會希望每張診療椅(per chair)都配一台 iTero 掃描器。因此你不能用「每位醫師一台」的方式來看單位數。你必須用「該診所的診療椅數」來看單位數。所以我會說,很明顯我們目前在矯正專科端的滲透率高於一般牙科端。但就像 Shirley 剛剛提到的,美國有 150,000 位 GP,我們在那一端從這個角度來看其實還幾乎沒有真正開始。而這類掃描器在 Invisalign 與修復性(restorative)應用之間也有不錯的平衡。
So if you're worried about a kind of a max out on penetration, that's not necessarily the way that we're thinking on a -- certainly, on a yearly basis. On the SDC volume piece, I don't think we've given out that data. And don't think we necessarily want to do that both for our sake and SDC's, too.
所以如果你擔心滲透率會「見頂」,那並不是我們思考的方式——至少以年度的角度來看更是如此。至於 SDC 量的部分,我不認為我們曾對外提供過那個數據。而且我們也不一定想這麼做,這對我們以及對 SDC 來說都是如此。
Ravi Misra - Associate
Ravi Misra - Associate
Great. And then if I could just get one more on just OpEx and investments. Some of the calls that we've spoken to is that dentists are pretty favorable, maybe shifting more of their cases towards Invisalign. Can you just talk a little bit about kind of the TFM, how that's kind of playing out as you've brought it to the U.S? And whether you feel like you need to expand and doing more investments to support further conversion of these cases to Invisalign?
很好。最後我再問一個關於營業費用(OpEx)與投資的問題。我們訪談到的一些看法是,牙醫對 Invisalign 的接受度相當高,可能會把更多案例轉向 Invisalign。你能否談談 TFM 的情況,尤其是你們把它帶到美國之後,目前進展如何?以及你們是否覺得需要擴大、投入更多資源,以支持更多案例轉換到 Invisalign?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
Yes, Ravi. First, I think your question is a great question. It's just how -- from a penetration standpoint, how do you drive more than what you do? TFM is one of it. I mean, we've really rolled that out strongly in North America this year. Our numbers are tremendous in the sense of when you have a customer who wants to dedicate time to really learn -- just again, think of TFM as kind of a learning curve as you have primarily an analog process and your whole office has worked around gluing wires and brackets and adjusting emergencies to people's teeth and what it look like when you go to more of a digital format. You're now at the front end of the digital system, how you work with ClinCheck and we -- these are doctors that come forward and say they want to devote 90 days, 120 days of just learning and just spending time to learn how to really ramp up in a digital format. And it works well. But it's self-selected in that case because doctors come forward who really want to do that and spend their time.
是的,Ravi。首先,我認為你的問題問得很好。從滲透率的角度來看,問題在於——你要如何把採用度推升到超過目前的水準?TFM 是其中一項。我的意思是,我們今年在北美確實大力推行。我們的數據非常亮眼,因為當你遇到一位客戶願意投入時間真正去學習——再說一次,把 TFM 想成一個學習曲線:你原本主要是類比流程,整個診所都圍繞著黏線、托槽,以及處理各種緊急狀況來調整病人的牙齒;而當你轉向更數位化的模式時會是什麼樣子。你現在站在數位系統的前端,學習如何使用 ClinCheck 與我們合作——這些醫師會主動站出來說,他們想投入 90 天、120 天來學習,花時間學會如何在數位化模式下真正加速上量。而且效果很好。但在這種情況下它是自我篩選的,因為會主動站出來的醫師,是真的想這麼做並願意投入時間的人。
I'd also say the other thing I've learned in this job over the last 2 years is how important peer-to-peer is from a growth standpoint. It's having really good, strong doctors that can communicate to other doctors about how to use Invisalign. We see this not just in North America. We see it all over the world. It's critical. We've ramped up new programs, like IOMP and some other things, that are just really helping in a sense both across the orthodontic community and also across the GP community do it. So those are the 2 big programs that, say, we use to address the question that you have about how you ramp up doctors.
我也想說,過去 2 年做這份工作我學到的另一件事,是從成長角度來看,同儕對同儕(peer-to-peer)的重要性。也就是要有非常優秀、很有影響力的醫師,能向其他醫師溝通如何使用 Invisalign。我們不只在北美看到這點。我們在全球各地都看得到。這非常關鍵。我們加速推出了新的計畫,例如 IOMP 以及其他一些項目,這些在某種程度上確實很有幫助,既能在齒顎矯正社群之間推動,也能在一般牙醫(GP)社群之間推動。所以,這就是我們用來回應你「如何讓醫師加速上量」這個問題的兩大計畫。
Ravi Misra - Associate
Ravi Misra - Associate
Great. And then if I could squeeze one last one in. And just given the landscape in the dental industry out there right now and your cash balance, any type of color on what kind of acquisitions that you guys would be potentially interested in beyond the -- I appreciate that you've been kind of building out the OUS kind of sales base by some of the distributor purchases, but anything beyond that, that we can kind of think about?
很好。然後如果我可以再塞最後一個問題。考量目前牙科產業的整體環境以及你們的現金餘額,能否談談你們可能有興趣的併購類型——除了……我理解你們透過收購一些經銷商來建立 OUS 的銷售基礎,但除此之外,還有沒有其他我們可以思考的方向?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
I mean, I'll call that an IQ question kind of, okay, and the way I'd answer that is we're in the clear aligner business. And anything that helps us to sell more clear aligners directly, it doesn't have to be explained to be in our wind -- our range. So that's why we have a scanner business. We have a scanner business, not from a diversification standpoint; we have a scanner business because it allows us to sell more clear aligners. And so this -- you're not looking -- I don't care how much cash we have. We're not looking to be a diversified dental company. We do clear aligners.
我的意思是,我會把這稱作一個「IQ 問題」,好嗎?我的回答方式是:我們是在做透明矯正器(clear aligner)生意。任何能幫助我們直接賣出更多透明矯正器的事情,都不需要太多解釋,就會落在我們的——我們的範圍之內。所以這就是為什麼我們有掃描器業務。我們做掃描器業務不是為了多角化;我們做掃描器業務是因為它能讓我們賣出更多透明矯正器。所以——你不是在看——我不在乎我們有多少現金。我們不打算成為一家多角化的牙科公司。我們做透明矯正器。
Operator
Operator
Our last question comes from the line of Steve Beuchaw of Morgan Stanley.
我們最後一個問題來自 Morgan Stanley 的 Steve Beuchaw。
Zachary Ryan Wachter - Research Associate
Zachary Ryan Wachter - Research Associate
This is actually Zach Wachter on for Steve. Joe, just one question on Invisalign Go. I'm wondering if you could just update us, Joe, on the ramp there and how we should think about the timing of Go given that the GP channel seems to be doing a bit better here. When should we think about Go making a more substantial impact?
我其實是代替 Steve 的 Zach Wachter。Joe,我只有一個關於 Invisalign Go 的問題。我想請你更新一下 Go 的爬坡情況,以及鑑於 GP 通路看起來表現稍微好一些,我們應該如何看待 Go 的時程。我們應該在什麼時候預期 Go 會帶來更顯著的影響?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
I think, Zach, the best way to think about that is if you take a step back from this whole thing, our approach with GP channel more and more is we make it easy and efficient. And Go is a product like that. It's a product where you can adapt quickly from a GP standpoint. It does simple cases. Most Gos are less than, I think, 15 aligners or so. We've adopted the protocols to make it simpler for doctors to do also. So I would say don't just take Go. You could look in the future. We'll have a series of more simple kind of products and systems that we'll introduce to GPs to get through. [iGo] is just the first one of those. That's not to down-sell iGo , but as we learn from iGo , we can continue to iterate on that product line and make new offerings. So -- but it's a big part of our GP strategy overall. It's having the right product and the right kind of system that it features that make it really simple for the GP doctor.
Zach,我認為最好的思考方式是,如果你先退一步看整體,我們對 GP 通路的做法越來越是:讓它變得容易且有效率。而 Go 就是這樣的產品。這是一個從 GP 角度可以快速上手、快速調整的產品。它處理的是簡單病例。大多數 Go 病例少於——我想——大約 15 副矯正器左右。我們也採用了相關流程(protocols),讓醫師操作起來更簡單。所以我會說,不要只看 Go。你可以展望未來。我們會推出一系列更簡單的產品與系統,提供給 GP 來使用與導入。[iGo] 只是其中的第一個。這不是要貶低 iGo,但隨著我們從 iGo 學到更多,我們可以持續迭代這條產品線並推出新的方案。所以——但它確實是我們整體 GP 策略的重要一環。也就是要有正確的產品,以及正確的系統與功能,讓 GP 醫師使用起來非常簡單。
Zachary Ryan Wachter - Research Associate
Zachary Ryan Wachter - Research Associate
Got you, okay. And just last one then. As far as the distributors that you acquired in EMEA and Brazil go, was there any meaningful impact in the quarter from that?
了解,好的。那最後一個問題。就你們在 EMEA 和巴西收購的經銷商而言,這一季是否帶來任何顯著影響?
Joseph M. Hogan - CEO, President and Director
Joseph M. Hogan - CEO, President and Director
I wouldn't -- no material impact. And you usually don't see material impact in that for 18 months or 2 years. So next year at this time is a great time to ask that question, Zach.
我不會——沒有實質性的影響。而且通常在那方面,你要到 18 個月或 2 年後才會看到實質性影響。所以明年這個時候再問這個問題會是個很好的時點,Zach。
Operator
Operator
There are no further questions over the audio portion of the conference. I would now like to turn the conference back over to management for closing remarks.
音訊會議部分沒有其他問題。我現在想把會議交回管理層做結語。
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
Shirley Stacy - Vice-President of Corporate Communications and Investor Relations
Thank you, everyone, for joining us on our conference call today. This concludes our formal remarks. If you have any questions, please reach out to the Investor Relations department. Have a great day.
感謝各位今天參加我們的電話會議。以上為我們的正式發言。如有任何問題,請聯繫投資人關係部門。祝各位有美好的一天。
Operator
Operator
This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time. Have a wonderful rest of your day.
今天的會議到此結束。感謝各位的參與。您現在可以掛斷電話線。祝各位今天剩餘時間愉快。